We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Supreme Court refused to hear appeals brought by Purdue Pharma LP for a patent infringement case centered on reformulations of the painkiller OxyContin, clearing several barriers to the development of generics. Read More
The Federal Trade Commission is backing Mylan’s request for a rehearing before a panel of appellate judges on the dismissal of an antitrust lawsuit against Warner Chilcott and Mayne Pharmaceuticals. Read More
A nearly two-year antitrust investigation by the Justice Department that involves more than a dozen generics makers could result in price-collusion charges before the year ends, according to a source familiar with the matter. Read More
The UK Court of Appeal affirmed an earlier ruling that invalidated Pfizer’s patent claims for Lyrica and ruled generics would not lead to infringements. Read More
Drugmakers have expressed concern about the German government’s proposal to restrict drug pricing — contending that the measure penalizes research and development. Read More
The antitrust division of the Justice Department has issued subpoenas to a Mylan executive and certain employees over the pricing of four generic drugs. Read More
A federal appellate court is remanding a False Claims Act suit that alleges Fresenius overcharged Medicare for dialysis treatments — ruling that the whistleblower lacked standing based on a reliance on secondhand accounts. Read More